Tachycardia or tachyarrhythmia is used to describe the presence of cardiac rhythm abnormality in states when cardiac rate is increased to >100 bpm.
Divided into supraventricular and ventricular tachycardia.
Signs and symptoms related to rapid heart rate are altered sensorium,
angina, shortness of breath, myocardial infarction, hypotension and
other signs of shock (eg cold clammy skin, low urine output), heart
failure or pulmonary congestion.
The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.
The use of a wearable cardioverter-defibrillator (WCD) may be a suitable alternative for paediatric patients with life-threatening ventricular arrhythmias who are not candidates for implantable cardioverter-defibrillators (ICDs), a recent study showed.
Treatment with the nonsteroidal, selective mineralocorticoid receptor antagonist finerenone reduced chronic kidney disease (CKD) progression and cardiovascular (CV) event risk in patients with CKD and type 2 diabetes (T2D), according to the FIDELIO-DKD* study presented at ASN Kidney Week 2020.
A dietary pattern (DP) characterized by high intakes of eggs, fish, milk, and other dairy products appears to confer protective benefits against incident cardiovascular disease (CVD) in women, reveals a study.